Shaw, R., Yoon, J. J., Johnston, H., Davidson, M. B., Siddon, A. J., Shallis, R. M., Chen, E. C., Burkart, M., Oh, T. S., Iyer, S. G., Madarang, E., Muthiah, C., Kassner, J., Rampal, R. K., Guru Murthy, G. S., Bradley, T. J., Abaza, Y., Garcia, J. S., Gupta, V., … Patel, A. A. (2025). Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy. Blood Advances. https://doi.org/10.1182/bloodadvances.2024015712

Mboizi, V., Nabaggala, C., Munube, D., Ssenkusu, J. M., Kasirye, P., Kamya, S., Kawooya, M. G., Boehme, A., Minja, F., Mupere, E., Opoka, R., Rosano, C., Idro, R., & Green, N. S. (2024). Hydroxyurea therapy for neurological and cognitive protection in pediatric sickle cell anemia in Uganda (BRAIN SAFE II): Protocol for a single-arm open label trial. Contemporary Clinical Trials Communications, 42, 101404. https://doi.org/10.1016/j.conctc.2024.101404

Gui, G., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., De Lima, M. J. G., Litzow, M. R., Kebriaei, P., Saber, W., Spellman, S. R., … Hourigan, C. S. (2024). Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02449-2

Patel, A. A., Yoon, J. J., Johnston, H., Davidson, M. B., Shallis, R. M., Chen, E. C., Burkart, M., Oh, T. S., Iyer, S. G., Madarang, E., Muthiah, C., Gross, I., Dean, R., Kassner, J., Viswabandya, A., Madero-Marroquin, R., Rampal, R. K., Guru Murthy, G. S., Bradley, T., … Odenike, O. (2024). Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Advances, 8(13), 3468–3477. https://doi.org/10.1182/bloodadvances.2024012880

Mellgard, G., Gilligan, M., Cliff, E. R. S., Bhutani, D., Mohyuddin, G. R., Eisenberger, A., Lentzsch, S., & Chakraborty, R. (2024). Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. HemaSphere, 8(3). Portico. https://doi.org/10.1002/hem3.61

Hughes, M., & Lentzsch, S. (2023). Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis. Therapeutics and Clinical Risk Management, Volume 19, 1063–1074. https://doi.org/10.2147/tcrm.s325859

Yalcinkaya, M., Liu, W., Thomas, L.-A., Olszewska, M., Xiao, T., Abramowicz, S., Papapetrou, E. P., Westerterp, M., Wang, N., Tabas, I., & Tall, A. R. (2023). BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis. Circulation, 148(22), 1764–1777. https://doi.org/10.1161/circulationaha.123.065344

Cortes, J., Jurcic, J., Baer, M. R., Blum, W., Ferrell, P. B., Jonas, B. A., Lee, S., Mims, A., Patel, S. A., Schiller, G. J., Yang, J., & Watts, J. M. (2023). Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax. Blood, 142(Supplement 1), 2888–2888. https://doi.org/10.1182/blood-2023-187861

Wang, E. S., Jonas, B. A., Watts, J. M., Jurcic, J., Ferrell, P. B., Dinner, S. N., Yang, J., Seiter, K., Mims, A., Donnellan, W. B., Blum, W., & Cortes, J. (2023). Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia. Blood, 142(Supplement 1), 6047–6047. https://doi.org/10.1182/blood-2023-187584

Fu, J., Li, S., MA, H., Brown, L. M., Mapara, M., & Lentzsch, S. (2023). Checkpoint Inhibitor PD-1H/VISTA Affects Myeloma Bone Disease By Osteoclast Cytoskeleton Remodeling. Blood, 142(Supplement 1), 6610–6610. https://doi.org/10.1182/blood-2023-189820

Proli, A., Sawas, A., Ho, G., Wang, J., & Fullerton, C. (2023). Methods for Identification of Blood Product Transfusions in a Cohort of Myelofibrosis Patients: An Assessment of Data Capture Using Insurance Claims and Electronic Health Record Abstraction. Blood, 142(Supplement 1), 7292–7292. https://doi.org/10.1182/blood-2023-189374

Patel, A. A., Yoon, J. J., Johnston, H., Davidson, M. B., Viswabandya, A., Shallis, R. M., Chen, E. C., Burkart, M., Oh, T. S., Iyer, S. G., Madarang, E., Muthiah, C., Dean, R., Kassner, J., Rampal, R. K., Guru Murthy, G. S., Bradley, T., Abaza, Y., Garcia, J. S., … Odenike, O. (2023). Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies. Blood, 142(Supplement 1), 3192–3192. https://doi.org/10.1182/blood-2023-174790

Lapolla, B., Gordon, E., Fahmy, L., Schreidah, C., Adeuyan, O., Magro, C., & Geskin, L. (2023). 214 Angiolymphoid hyperplasia with eosinophilia and kimura disease: a case of clinical and histopathological discrepancy and response to dupilumab. Journal of Investigative Dermatology, 143(11), S368. https://doi.org/10.1016/j.jid.2023.09.222

Cochran, J. D., Yura, Y., Thel, M. C., Doviak, H., Polizio, A. H., Arai, Y., Arai, Y., Horitani, K., Park, E., Chavkin, N. W., Kour, A., Sano, S., Mahajan, N., Evans, M., Huba, M., Naya, N. M., Sun, H., Ban, Y. H., Hirschi, K. K., … Walsh, K. (2023). Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction. Circulation, 148(15), 1165–1178. https://doi.org/10.1161/circulationaha.123.064170

Yu, Z., Fidler, T. P., Ruan, Y., Vlasschaert, C., Nakao, T., Uddin, M. M., Mack, T., Niroula, A., Heimlich, J. B., Zekavat, S. M., Gibson, C. J., Griffin, G. K., Wang, Y., Peloso, G. M., Heard-Costa, N., Levy, D., Vasan, R. S., Aguet, F., Ardlie, K. G., … Natarajan, P. (2023). Genetic modification of inflammation- and clonal hematopoiesis–associated cardiovascular risk. Journal of Clinical Investigation, 133(18). https://doi.org/10.1172/jci168597

Coughlan, A., Klijn, S. L., Xiao, H., White, B., Litkiewicz, M., Kadambi, A., Sichevaya, A., Hnoosh, A., Miteva, D., & Yucel, A. (2023). POSTER: MDS-008 Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS). Clinical Lymphoma Myeloma and Leukemia, 23, S180. https://doi.org/10.1016/s2152-2650(23)00575-x

Gertz, M., Abonour, R., Gibbs, S., Finkel, M., Landau, H., Lentzsch, S., Lin, G., Mahindra, A., Quock, T., Rosenbaum, C., Rosenzweig, M., Sidana, S., Tuchman, S., Witteles, R., Yermilov, I., & Broder, M. (2023). Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis. ClinicoEconomics and Outcomes Research, Volume 15, 673–680. https://doi.org/10.2147/ceor.s412079

Oberlin, A., Krenitsky, N. M., Gandhi, C., Akpan, I. J., Eisenberger, A., Landau, R., Yurteri-Kaplan, L., Nathan, L., Sheen, J.-J., LaSala, A., & D’Alton, M. (2023). Acquired Hemophilia A: A Rare, Acquired Coagulopathy in the Postpartum Setting. American Journal of Perinatology Reports, 13(04), e85–e88. CLOCKSS. https://doi.org/10.1055/a-2198-7888

Murthy, G. S. G., Kim, S., Estrada-Merly, N., Abid, M. B., Aljurf, M., Assal, A., Badar, T., Badawy, S. M., Ballen, K., Beitinjaneh, A., Cerny, J., Chhabra, S., DeFilipp, Z., Dholaria, B., Perez, M. A. D., Farhan, S., Freytes, C. O., Gale, R. P., Ganguly, S., … Saber, W. (2023). Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica, 108(7), 1900–1908. https://doi.org/10.3324/haematol.2022.281958

Sarkaria, S. M., Zhou, J., Bao, S., Zhao, W., Fang, Y., Que, J., Bhagat, G., Zhang, C., & Ding, L. (2023). Systematic dissection of coordinated stromal remodeling identifies Sox10 glial cells as a therapeutic target in myelofibrosis. Cell Stem Cell, 30(6), 832-850.e6. https://doi.org/10.1016/j.stem.2023.05.002

Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., Zeidner, J. F., Garcia-Manero, G., Jeyakumar, D., Komrokji, R., Lancet, J., Kantarjian, H. M., Gu, L., Zhang, Y., Tan, A., … Daver, N. G. (2023). Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of Clinical Oncology, 41(15), 2815–2826. https://doi.org/10.1200/jco.22.01794

De, A., Williams, S., Yao, Y., Jin, Z., Brittenham, G. M., Kattan, M., Lovinsky-Desir, S., & Lee, M. T. (2023). Acute chest syndrome, airway inflammation and lung function in sickle cell disease. PLOS ONE, 18(3), e0283349. https://doi.org/10.1371/journal.pone.0283349

Vela, P. S., Wang, R., Tran, D., Benitez, A. M., Krishnan, A., O’Connor, K., Liu, W., Kleppe, M., Bowman, R., Cai, S., Shih, A., Wang, N., Esteller, M., Bolton, K., Tall, A., & Levine, R. (2023). 3168 – TARGETING JAK1 SIGNALING FOR MOLECULAR PREVENTION IN CLONAL HEMATOPOIESIS. Experimental Hematology, 124, S133. https://doi.org/10.1016/j.exphem.2023.06.275

Zeidan, A. M., Platzbecker, U., Garcia-Manero, G., Sekeres, M. A., Fenaux, P., DeZern, A. E., Greenberg, P. L., Savona, M. R., Jurcic, J. G., Verma, A. K., Mufti, G. J., Buckstein, R., Santini, V., Shetty, J. K., Ito, R., Zhang, J., Zhang, G., Ha, X., Backstrom, J. T., & Komrokji, R. S. (2022). Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood, 140(20), 2170–2174. https://doi.org/10.1182/blood.2022016171

Oh, S. T., Mesa, R., Harrison, C., Bose, P., Gerds, A. T., Heaney, M. L., Gupta, V., Scott, B. L., Kiladjian, J.-J., Lucchesi, A., Buckley, S., Tyavanagimatt, S., Roman-Torres, K., Mascarenhas, J., & Verstovsek, S. (2022). Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis. Blood, 140(Supplement 1), 1518–1521. https://doi.org/10.1182/blood-2022-156936

Mosialou, I., Ali, A. M., Adams, R., Corper, A., Woods, C. M., Fan, X., Raza, A., & Kousteni, S. (2022). Therapeutic Anti-Jagged1 Antibody Targeting Osteoblast-Related Myeloid Dysplasia to Overcome Standard of Care Resistance. Blood, 140(Supplement 1), 2902–2902. https://doi.org/10.1182/blood-2022-167042

Zhang, C., Tremblay, D., Magnotti, J., Ronner, L., Podoltsev, N. A., Gotlib, J., Heaney, M. L., Kuykendall, A., O’Connell, C. L., Fleischman, A. G., Mesa, R., Yacoub, A., Mascarenhas, J., & Shammo, J. M. (2022). Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis. Blood, 140(Supplement 1), 9693–9695. https://doi.org/10.1182/blood-2022-157873

Granat, L. M., Li, H., Anwer, F., Sheu, M., Faiman, B. M., Khouri, J., Mazzoni, S., Valent, J., Samaras, C. J., Chakraborty, R., Chaulagain, C. P., van Heeckeren, W. J., & Williams, L. S. (2022). Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma. Blood, 140(Supplement 1), 4290–4291. https://doi.org/10.1182/blood-2022-168040

Tremblay, D., Srisuwananukorn, A., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A., O’Connell, C. L., Shammo, J. M., Fleischman, A., Mesa, R., Yacoub, A., Hoffman, R., Moshier, E., Zubizarreta, N., & Mascarenhas, J. (2022). European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera. HemaSphere, 6(6), e721. https://doi.org/10.1097/hs9.0000000000000721

Miller, P. G., Qiao, D., Rojas-Quintero, J., Honigberg, M. C., Sperling, A. S., Gibson, C. J., Bick, A. G., Niroula, A., McConkey, M. E., Sandoval, B., Miller, B. C., Shi, W., Viswanathan, K., Leventhal, M., Werner, L., Moll, M., Cade, B. E., Barr, R. G., … Correa, A. (2022). Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood, 139(3), 357–368. https://doi.org/10.1182/blood.2021013531

Lieu, Y. K., Liu, Z., Ali, A. M., Wei, X., Penson, A., Zhang, J., An, X., Rabadan, R., Raza, A., Manley, J. L., & Mukherjee, S. (2021). SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences, 119(1). https://doi.org/10.1073/pnas.2111703119